PATENT CLAIM ANALYSIS

Application Number: 15990935
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "263210"]

Abstract:
The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.

Claim (Index 12):
The method according to  claim 1 , wherein 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, or a pharmaceutically acceptable salt thereof, is administered in combination with one or more further active substances selected from antidiabetics, active substances that lower the blood sugar level, active substances that lower the lipid level in the blood, active substances that raise the HDL level in the blood, active substances that lower the blood pressure, active substances that are indicated in the treatment of atherosclerosis, and active substances that are indicated in the treatment of obesity.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 93.0
- Lexical Diversity: 1.14286
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13057295', '14294630', '15287228', '13143370', '11916356']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7683146157713828
- 35 USC 102 Novelty (BERT): 0.5877133464885776
- Combined Prediction Score: 0.7502544888431023
- Mean Citation Score: 377.57612
- Max Citation Score: 507.50964000000016
- Similarity Product: 431.2008595110083

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test